Related Experiment Video
Updated: Mar 11, 2026
11:20
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
Published on: March 29, 2018
8.1K
World's First Clinical Case of Gene-Activated Bone Substitute Application
I Y Bozo1, R V Deev2, A Y Drobyshev3
1Department of Maxillofacial and Plastic Surgery, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia; Human Stem Cells Institute, Moscow, Russia; Department of Maxillofacial Surgery, A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia.
Case Reports in Dentistry
|November 29, 2016
Summary
This study introduces a novel gene-activated bone substitute for large bone defects. Early clinical results show promising safety and efficacy in treating complex mandibular nonunions.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Orthopedic Surgery
Background:
- Large bone defects pose significant clinical challenges.
- Current treatments often have limitations in efficacy and patient outcomes.
- Gene-activated bone substitutes offer a potential advancement in bone regeneration.
Purpose of the Study:
- To evaluate the safety and efficacy of a novel gene-activated bone substitute in a clinical setting.
- To assess the bone regeneration potential in patients with large bone defects.
- To report the outcomes of the first patient treated with this innovative biomaterial.
Main Methods:
- A collagen-hydroxyapatite scaffold with plasmid DNA encoding vascular endothelial growth factor was used.
- The gene-activated bone substitute was implanted into a patient with complex mandibular nonunions.
- Clinical follow-up included imaging and assessment of bone density and defect repair over 12 months.
Main Results:
- No adverse events were reported during the 12-month follow-up period.
- Newly formed tissue density correlated with spongy bone density within 3 months.
- Successful elimination of a posterior mandibular nonunion was observed, though partial autograft resorption occurred.
Conclusions:
- The first clinical data suggest the gene-activated bone substitute is safe and shows promising efficacy for complex bone defects.
- This innovative biomaterial represents a potential breakthrough in treating challenging orthopedic and maxillofacial cases.
- Further investigation is warranted to optimize treatment strategies and confirm long-term outcomes.
